Swiss Franc Strength Puts Roche's Results in a Poor Light

Why It Matters

The results show that currency headwinds can mask underlying growth, and Roche’s diversified portfolio and pipeline are critical to maintaining its mid‑single‑digit sales trajectory despite a strong franc.

Key Takeaways

• Q1 revenue fell 5% as Swiss franc appreciated.
• FX‑neutral sales rose 6% to CHF 14.77 bn (~$16 bn).
• Pharma division grew 7% on constant‑currency basis.
• Ocrevus, Hemlibra, Vabysmo each posted ~6‑13% growth.
• Pipeline includes fenebrutinib BTK inhibitor and KRAS drug divarasib.

Pulse Analysis

Roche’s first‑quarter report shows a headline 5 % decline in revenue, driven primarily by the Swiss franc’s rally against the dollar amid heightened geopolitical risk. On a constant‑currency basis the group posted a 6 % increase, reaching CHF 14.77 billion – roughly $16 billion – and a 9 % gain versus the weakened U.S. dollar. The currency effect mirrors a broader trend among Swiss‑based pharmaceutical firms, where a stronger franc compresses reported sales despite solid underlying demand. Analysts therefore focus on the FX‑neutral growth to gauge true performance. Investors are therefore scrutinising Roche’s hedging strategy and its ability to sustain earnings momentum.

The pharma division’s headline sales slipped 4 % to CHF 11.47 billion (about $12.5 billion), but rose 7 % when stripped of currency distortions, underscoring the resilience of Roche’s core portfolio. Blockbusters Ocrevus, Hemlibra and Vabysmo each delivered double‑digit growth, contributing CHF 1.69 billion, CHF 1.19 billion and CHF 1.02 billion respectively. A notable 26 % surge in Xolair sales followed its recent FDA indication expansion into food‑allergy treatment. Together, these products offset the franc‑driven headwinds and reinforce Roche’s position in neurology, hematology and ophthalmology. The strong performance of these biologics also supports Roche’s dividend outlook.

Beyond current sales, Roche’s pipeline could sustain mid‑single‑digit growth through 2030. Phase‑3 data are expected this year for fenebrutinib, an oral BTK inhibitor targeting multiple sclerosis, and divarasib, a KRAS G12C agent for non‑small‑cell lung cancer, while late‑stage trials of Itovebi and Lunsumio aim at metastatic breast cancer and follicular lymphoma. The company’s $50 billion U.S. capital investment, designed to mitigate tariff risk, also signals a long‑term commitment to North‑American markets. If the projected 19 new product launches materialize, Roche will likely outpace peers despite currency volatility. Analysts project that the diversified pipeline could buffer future macro‑economic shocks.